English  |  正體中文  |  简体中文  |  Total items :0  
Visitors :  51519083    Online Users :  887
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"jia horng kao"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 436-485 of 1180  (24 Page(s) Totally)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-09-04T06:11:38Z A pilot study of add-on oral hypoglycemic agents in treatment-na?ve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin Hsu C.-S.; Hsu S.-J.; Lin H.H.; Tseng T.-C.; Wang C.-C.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:38Z Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients Wang C.-C.; Tseng T.-C.; Wang P.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:38Z Reduced toll-like receptor 9 expression on peripheral C D14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy Huang Y.-W.; Hsu C.-K.; Lin S.-C.; Wei S.-C.; Hu J.-T.; Chang H.-Y.; Liang C.-W.; Chen D.-S.; Chen P.-J.; Hsu P.-N.; Yang S.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:37Z Molecular mechanism and treatment of viral hepatitis-related liver fibrosis Su T.-H.; JIA-HORNG KAO; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:37Z Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: Optimizing use of peginterferon alfa Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:37Z Triple therapy for hepatitis C virus infection in patients receiving hemodialysis Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:36Z Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: Molecular mechanisms and clinical significance Yang H.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:36Z Risk stratification of HBV infection in Asia-Pacific region JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:36Z The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo Lin S.-R.; Yang H.-C.; Kuo Y.-T.; Liu C.-J.; Yang T.-Y.; Sung K.-C.; Lin Y.-Y.; Wang H.-Y.; Wang C.-C.; Shen Y.-C.; Wu F.-Y.; JIA-HORNG KAO; Chen D.-S.; Chen P.-J.
臺大學術典藏 2021-09-04T06:11:35Z What can we learn from hepatitis B virus clinical cohorts? Lin C.-L.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:35Z Hepatitis B virus infection and metabolic syndrome: Fact or fiction? Wang C.-C.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:35Z Asunaprevir-containing regimens for the treatment of hepatitis C virus infection Yang S.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:34Z Viral hepatitis: HBV cure-can we pin our hopes on immunotherapy? Yang H.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:34Z Treating immune-tolerant Hepatitis B Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:34Z Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: Comparison of genotypes B and C at various immune stages Liu C.-J.; Chen T.-C.; Chen P.-J.; Wang H.-Y.; Tseng T.-C.; Cheng H.-R.; Liu C.-H.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:33Z Hepatitis B virus genotypes and variants Lin C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:33Z Hepatitis B vaccination and prevention of hepatocellular carcinoma JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:33Z Reimbursement policies in the Asia-Pacific for chronic hepatitis B Lim S.G.; Amarapurkar D.N.; Chan H.L.-Y.; Crawford D.H.; Gane E.J.; Han K.-H.; Ahn S.H.; Jafri W.; Jia J.; JIA-HORNG KAO; Lesmana L.A.; Lesmana C.R.A.; Mohamed R.; Phiet P.H.; Piratvisuth T.; Sarin S.K.; Sollarno J.D.; Eguchi Y.; Mahtab M.-A.; Lee K.H.
臺大學術典藏 2021-09-04T06:11:32Z Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B Lin C.-L.; Liu C.-H.; Wang C.-C.; Liang C.-C.; Su T.-H.; Liu C.-J.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:32Z Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan Chen C.-L.; Yang J.-Y.; Lin S.-F.; Sun C.-A.; Bai C.-H.; You S.-L.; Chen C.-J.; JIA-HORNG KAO; Chen P.-J.; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:31Z On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy Huang Y.-W.; Takahashi S.; Tsuge M.; Chen C.-L.; Wang T.-C.; Abe H.; Hu J.-T.; Chen D.-S.; Yang S.-S.; Chayama K.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:31Z Perspectives and control of hepatitis B virus infection in Taiwan Lin C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:31Z Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients Wang C.-C.; Liu C.-H.; Lin C.-L.; Wang P.-C.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:30Z Reply to: Modulation of Toll-like receptor 9 expression on monocytes of viral hepatitis patients Huang Y.-W.; Yang S.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:30Z Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir Chen G.-Y.; Su T.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:30Z Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:29Z New insights into the evolutionary rate of hepatitis B virus at different biological scales Lin Y.-Y.; Liu C.; Chien W.-H.; Wu L.-L.; Tao Y.; Wu D.; Lu X.; Hsieh C.-H.; Chen P.-J.; Wang H.-Y.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:29Z Treating Immune-tolerant Hepatitis B Tseng, T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:29Z Improving clinical outcomes of chronic hepatitis B virus infection Su T.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:28Z Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection Song L.-W.; Liu P.-G.; Liu C.-J.; Zhang T.-Y.; Cheng X.-D.; Wu H.-L.; Yang H.-C.; Hao X.-K.; Yuan Q.; Zhang J.; JIA-HORNG KAO; Chen D.-S.; Chen P.-J.; Xia N.-S.
臺大學術典藏 2021-09-04T06:11:28Z Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection Hsu C.-S.; Liu W.-L.; Chao Y.-C.; Lin H.H.; Tseng T.-C.; Wang C.-C.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:28Z HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:27Z Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping Liu C.-H.; Liang C.-C.; Liu C.-J.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:27Z Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy Liang C.-C.; Liu C.-H.; Chung C.-S.; Lin C.-K.; Su T.-H.; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:27Z Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang W.-T.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:26Z Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system Liu J.; Tseng T.-C.; Yang H.-I.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Lu S.-N.; Wang L.-Y.; You S.-L.; Chen P.-J.; Chen C.-J.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:26Z Systematic review: Impact of interferon-based therapy on HCV-related hepatocellular carcinoma Hsu C.-S.; Chao Y.-C.; Lin H.H.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:25Z Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L.
臺大學術典藏 2021-09-04T06:11:25Z Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial Buti M.; Flisiak R.; JIA-HORNG KAO; Chuang W.-L.; Streinu-Cercel A.; Tabak F.; Calistru P.; Goeser T.; Rasenack J.; Horban A.; Davis G.L.; Alberti A.; Mazzella G.; Pol S.; Orsenigo R.; Brass C.
臺大學術典藏 2021-09-04T06:11:25Z Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:24Z Towards an HBV cure: State-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure Zeisel M.B.; Lucifora J.; Mason W.S.; Sureau C.; Beck J.; Levrero M.; Kann M.; Knolle P.A.; Benkirane M.; Durantel D.; Michel M.-L.; Autran B.; Cosset F.-L.; Strick-Marchand H.; Tr?po C.; JIA-HORNG KAO; Carrat F.; Lacombe K.; Schinazi R.F.; Barr?-Sinoussi F.; Delfraissy J.-F.; Zoulim F.
臺大學術典藏 2021-09-04T06:11:24Z A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan Bennett H.; Waser N.; Johnston K.; JIA-HORNG KAO; Lim Y.-S.; Duan Z.-P.; Lee Y.-J.; Wei L.; Chen C.-J.; Sievert W.; Yuan Y.; Li H.
臺大學術典藏 2021-09-04T06:11:23Z Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: A nation-wide cohort study Huang Y.-W.; Wang T.-C.; Yang S.-S.; Lin S.-Y.; Fu S.-C.; Hu J.-T.; Liu C.-J.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:23Z Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:23Z Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers Tseng T.-C.; Liu C.-J.; Yang H.-C.; Chen C.-L.; Yang W.-T.; Tsai C.-S.; Kuo S.F.-T.; Verbree F.C.; Su T.-H.; Wang C.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:22Z Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L.
臺大學術典藏 2021-09-04T06:11:22Z Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma Wang C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:21Z Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study Liu C.-H.; Sheng W.-H.; Sun H.-Y.; Hsieh S.-M.; Lo Y.-C.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu W.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:21Z Looking into the crystal ball: biomarkers for outcomes of HBV infection Yang H.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:21Z Hepatitis B virus: New therapeutic perspectives Lin C.-L.; Yang H.-C.; JIA-HORNG KAO

Showing items 436-485 of 1180  (24 Page(s) Totally)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
View [10|25|50] records per page